{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962797",
  "id": "02962797",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250627",
  "time": "0930",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250627/pdf/06l5g31f1vlzss.pdf",
  "summary": "- **First patient dosed in Phase II trial**: PD1-Vaxx Neo-POLEM trial investigates neoadjuvant (pre-surgery) use in dMMR/MSI-high colorectal cancer (15% of cases).  \n- **Multi-country recruitment**: Trial includes sites in Australia and the UK.  \n- **Addressable market**: Colorectal cancer is the third most common globally (1.2M annual cases, ~50% mortality); 80% are treatable at diagnosis.  \n\n*No material financial/capital markets impact identified (e.g., funding, dilution, or trial cost disclosures omitted).*  \n\n*Tailored summary focuses on clinical milestones relevant to valuation (trial progress/target indication) without operational fluff.*",
  "usage": {
    "prompt_tokens": 1386,
    "completion_tokens": 153,
    "total_tokens": 1539,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-26T23:41:08.931290"
}